Efficacy assessment of an active tau immunotherapy in Alzheimer’s disease patients with amyloid and tau pathology: a post hoc analysis of the “ADAMANT” randomised, placebo-controlled, double-blind, multi-centre, phase 2 clinical trial
- DOI
- 10.1016/j.ebiom.2023.104923
- Published
- 2024-01
- Container
- eBioMedicine
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.ebiom.2023.104923,
title = {Efficacy assessment of an active tau immunotherapy in Alzheimer’s disease patients with amyloid and tau pathology: a post hoc analysis of the “ADAMANT” randomised, placebo-controlled, double-blind, multi-centre, phase 2 clinical trial},
author = {Nicholas C. Cullen and Petr Novak and Duygu Tosun and Branislav Kovacech and Jozef Hanes and Eva Kontsekova and Michal Fresser and Stefan Ropele and Howard H. Feldman and Reinhold Schmidt and Bengt Winblad and Norbert Zilka},
year = {2024},
journal = {eBioMedicine},
doi = {10.1016/j.ebiom.2023.104923},
url = {https://doi.org/10.1016/j.ebiom.2023.104923}
}RIS
TY - JOUR TI - Efficacy assessment of an active tau immunotherapy in Alzheimer’s disease patients with amyloid and tau pathology: a post hoc analysis of the “ADAMANT” randomised, placebo-controlled, double-blind, multi-centre, phase 2 clinical trial AU - Nicholas C. Cullen AU - Petr Novak AU - Duygu Tosun AU - Branislav Kovacech AU - Jozef Hanes AU - Eva Kontsekova AU - Michal Fresser AU - Stefan Ropele AU - Howard H. Feldman AU - Reinhold Schmidt AU - Bengt Winblad AU - Norbert Zilka PY - 2024 JO - eBioMedicine DO - 10.1016/j.ebiom.2023.104923 UR - https://doi.org/10.1016/j.ebiom.2023.104923 ER -
APA
Cullen, N. C., Novak, P., Tosun, D., Kovacech, B., Hanes, J., Kontsekova, E., Fresser, M., Ropele, S., Feldman, H. H., Schmidt, R., Winblad, B., & Zilka, N. (2024). Efficacy assessment of an active tau immunotherapy in Alzheimer’s disease patients with amyloid and tau pathology: a post hoc analysis of the “ADAMANT” randomised, placebo-controlled, double-blind, multi-centre, phase 2 clinical trial. eBioMedicine. https://doi.org/10.1016/j.ebiom.2023.104923
Source records
- crossref · retrieved 2026-09-26T14:11:23.278Z